Early response to vunakizumab and its baseline predictors in patients with moderate-to-severe plaque psoriasis: a <i>post hoc</i> analysis of a phase-III trial
Early response rate to vunakizumab was 54.0% in patients with moderate-to-severe plaque psoriasis, where female gender and naïve status to local therapy predicted early response.
Authors
- Jinrong Zeng (ORCID: https://orcid.org/0000-0002-3355-9586)
- Jianyun Lu (ORCID: https://orcid.org/0000-0002-4757-6141)
- Yangyiyi Yu
Institutions
- Central South University (CN)
- Third Xiangya Hospital (CN)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1080/09546634.2025.2564810
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00